Effect of supplementation in treatment of pregnant women at risk for intrauterine growth restrictio
Phase 3
- Conditions
- Pregnancy.Sequelae of complication of pregnancy, childbirth and the puerperium
- Registration Number
- IRCT201601045623N64
- Lead Sponsor
- Vice chancellor for research, Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Pregnant women at risk for intrauterine growth restriction
Aged 18 to 40 years
Exclusion Criteria
Taking selenium supplements during past 3 months
Hypo- and hyperthyroidism
Urinary tract infection
Pre-eclampsia
Hypertension
Diseases related to increased inflammation
Smokers
Kidney or liver diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total antioxidant. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Spectrophotometry.;Pulsatility index. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Sonography.
- Secondary Outcome Measures
Name Time Method Insulin. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Enzymatic kit.;Cholesterol. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Enzymatic kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Enzymatic kit.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 10 weeks of intervention. Method of measurement: Enzymatic kit.